Immune checkpoint inhibitors have emerged as a remarkable treatment option for diverse
cancer types. However, a significant number of patients on checkpoint inhibitors develop …

Monoclonal antibodies (mAbs) have been used in the treatment of various diseases for over
20 years and combine high specificity with generally low toxicity. Their pharmacokinetic …

Background Fluoropyrimidine-based chemotherapy plus the anti–vascular endothelial
growth factor (VEGF) antibody bevacizumab is standard first-line treatment for metastatic …

Background Hypertension (HTN) is an on-target effect of the vascular endothelial growth
factor pathway inhibitor, sunitinib. We evaluated the association of sunitinib-induced HTN …

Sorafenib has been considered the standard of care for patients with advanced
unresectable hepatocellular carcinoma (HCC) since 2007 and numerous studies have …

The spectrum of cardiac side-effects of cancer chemotherapy has expanded with the
development of combination, adjuvant and targeted chemotherapies. Their administration in …

It has been nearly 9years since the FDA (Food and Drug Administration) approved the first
anti-angiogenic drug (bevacizumab) for treatment of metastatic colorectal cancer. Other …

Angiogenesis—one of the hallmarks of cancer—has emerged as a valid therapeutic target in
oncology. The VEGF system represents a key mediator of tumor-initiated angiogenesis and …

Abstract Purpose of Review While vascular endothelial growth factor receptor inhibitors
(VEGFRis) have dramatically improved cancer survival, these drugs cause hypertension in a …

The humanized monoclonal antibody bevacizumab (Avastin®) has been available in the EU
since 2005. Results of phase III trials demonstrate that adding intravenous bevacizumab to …